βIII‐tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c‐Met positive non‐small cell lung cancer cells

Abstract

Lung cancer is one of the most common cancer types and remains a leading cause of cancer-related mortality worldwide. 1 The most common sub-type of lung cancer, non-small cell lung carcinoma (NSCLC), represents more than 80% of cases and has a dismal 5-year survival rate of less than 15%. 2 Chemotherapy remains the most effective treatment option however problems with drug resistance and toxicity present major clinical challenges. 3 Microtubules form a major component of the cell cytoskeleton and alterations in the expression of microtubule proteins are increasingly correlated with more aggressive and treatment-refractory cancers. 3 Intracellular signalling

Novel 8-Methoxycoumarin-3-Carboxamides with potent anticancer activity against liver cancer via targeting caspase-3/7 and β-tubulin polymerization

“…These isotypes have been found to have a correlation with aggressive disease, increased metastatic potential, and a higher likelihood of metastatic relapse in patients [ 33 ]. Among these isotypes, β-tubulin expression has been the primary focus of investigation [ 34 ]. Clinical data has demonstrated a significant association between elevated levels of β-tubulin protein expression and the manifestation of aggressive clinical characteristics as well as unfavorable prognosis in various types of cancer, such as pancreatic, glioblastoma, gastric, ovarian, breast, colorectal, and prostate.…”